Roche

In December 2018, C4 Therapeutics and Roche updated the terms of their strategic collaboration, which had initially commenced in January 2016. Under this updated arrangement, C4T develops degraders targeting a specified set of proteins through defined pre-clinical or early clinical milestones and Roche has exclusive options for worldwide rights to continue development and commercialize products arising from the collaboration.